The Ozempic-for-Drinking Trial Just Published Real Numbers. The Headline Effect Missed Its Own Primary Target.

A new randomized trial found oral semaglutide cut heavy drinking days and naturalistic craving. It also missed the lab-measured craving endpoint researchers had pre-registered as their main outcome — and that gap is the most useful part of the data.

A Phase 2 trial of oral semaglutide for alcohol use disorder found real reductions in heavy drinking days and craving — but missed its own pre-registered primary endpoint. Here's what that gap means, and why the VA is running the next version now.